show me the money

10 Houston billionaires bank spots on Forbes' 2020 list of richest Americans

Rich Kinder, and his wife, Nancy, join an impressive list of Texans on the 2020 edition of the Forbes 400. Photo by Michelle Watson/Catchlight Group

In a booming, opportunity city full of tycoons, which billionaire reigns supreme? That honor goes to Richard Kinder, the pipeline mogul worth $6.2 billion — who is also a familiar name in philanthropic circles as a chief benefactor of Memorial Park. Locals may also recognize his name on the new Museum of Fine Arts, Houston building.

Kinder, and his wife, Nancy, join an impressive list of Texans on the 2020 edition of the Forbes 400, which ranks the 400 richest Americans and was released September 8. (See their methodology here.) "Pandemic be damned: America's 400 richest are worth a record $3.2 trillion, up $240 billion from a year ago, aided by a stock market that has defied the virus," Forbes writes.

Around Houston, the richest-of-the-rich list looks similar to recent years. Here's how local billionaires rank nationally in 2020 and how their wealth has fared:

Houston:

  • Richard Kinder — $6.2 billion, No. 103. Last year: $7.5 billion.
  • Pipeline heirs Dannine Avara, Scott Duncan, Milane Frantz, and Randa Duncan Williams — $4.8 billion each, No. 139. Last year: $6.3 billion.
  • Houston Rockets owner and restaurant kingpin Tilman Fertitta — $4.1 billion, No. 181. Last year: $4.9 billion.
  • Toyota titan Dan Friedkin of Houston — $4.1 billion, No. 181. Last year: $4 billion.
  • Houston Texans co-founder Janice McNair — $3.9 billion, No. 197. Last year: $4 billion.
  • Houston energy executive Jeffery Hildebrand — $3.6 billion, No. 222. Last year: $3.8 billion.
  • Former hedge fund manager John Arnold — $3.3 billion, No. 249. Last year: $3.3 billion.

Meanwhile, Walmart heiress Alice Walton of Fort Worth has retained her status as the richest Texan and America's richest woman in 2020, with a net worth estimated this year at $62.3 billion. That compares with $51.4 billion in 2019.

Walton moved up from No. 11 last year to No. 10 this year in the Forbes ranking of the richest Americans.

From 2019 to 2020, Walton's net worth jumped by $10.9 billion. To give you an idea of how much money that is, the size of the economy in Africa's Republic of Congo totaled $10.8 billion in 2019. Walton's entire net worth is slightly more than the size of the Costa Rican economy (nearly $61.8 billion in 2019).

Here's the regional breakdown for Texas' remaining Forbes 400 billionaires.

Dallas-Fort Worth:

  • Dallas Cowboys owner Jerry Jones — $8.6 billion, No. 56. Last year: $8.6 billion.
  • Dallas banker and real estate investor Andy Beal — $7.6 billion, No. 67. Last year: $9.8 billion.
  • Fort Worth oil and gas heir Robert Bass — $4.8 billion, No. 139. Last year: $4.9 billion.
  • Dallas oil and gas heir Ray Lee Hunt — $4.6 billion, No. 154. Last year: $5.2 billion.
  • Dallas Mavericks owner Mark Cuban — $4.2 billion, No. 177. Last year: $4.1 billion.
  • Margot Birmingham Perot, widow of Dallas tech entrepreneur Ross Perot — $4 billion, No. 186. Last year: $4.2 billion.
  • Fort Worth private equity titan David Bonderman — $4 billion, No. 186. Last year: $3.7 billion.
  • Omni Hotels and Gold's Gym king Robert Rowling of Dallas — $3.9 billion, No. 197. Last year: $5.5 billion.
  • Oil and gas chief Trevor Rees-Jones of Dallas — $3.5 billion, No. 228. Last year: $3.7 billion.
  • Dallas pipeline executive Kelcy Warren — $2.8 billion, No. 299. Last year: $4.3 billion.
  • Dallas real estate honcho H. Ross Perot Jr. — $2.5 billion, No. 339. Last year: $2.2 billion.
  • Fort Worth oil heir Sid Bass — $2.3 billion, No. 359. Last year: $3.1 billion.
  • Dallas banker Gerald Ford — $2.1 billion, No. 391. Last year: $2.3 billion.

Austin:

  • Michael Dell, tech magnate — $35.6 billion, No. 18. Last year: $32.3 billion.
  • Robert Smith, private equity entrepreneur — $6.2 billion, No. 125. Last year: $5 billion.
  • Bert "Tito" Beveridge, vodka tycoon — $4.6 billion, No. 154. Last year: $4.2 billion.
  • Thai Lee, tech entrepreneur — $3.1 billion, No. 268. Last year: $3 billion.
  • Joe Liemandt, software entrepreneur — $3 billion, No. 278. Last year: $3 billion.
  • John Paul DeJoria, hair care and tequila mogul — $2.7 billion, No. 319. Last year: $3.1 billion.
  • Jim Breyer, venture capitalist — $2.4 billion, No. 353. Last year: $2.5 billion. (Breyer recently relocated from Silicon Valley to Austin).
  • Brian Sheth, private equity entrepreneur — $2.3 billion, No. 359. Last year: $2.2 billion.

Of note, in just one year, Dell's net worth soared by $3.3 billion — more than the entire net worth of fellow Austin billionaire Thai Lee. The chairman and CEO of the Round Rock-based tech company that bears his name is Austin's richest resident.

Elsewhere in Texas:

  • Walmart heiress Ann Walton Kroenke — $8.4 billion, No. 58. Last year: $7.5 billion.
  • Real estate, sports, and entertainment big shot Stan Kroenke — $8.3 billion, No. 59. Last year: $9.7 billion. (The Kroenkes live on a massive ranch near the North Texas town of Vernon.)
  • Investor and former grocery distributor Drayton McLane Jr. of Temple — $2.8 billion, No. 299. Last year: $2.6 billion. McLane is former owner of the Houston Astros.
  • Hearing-aid mogul Bill Austin of Brownsville — $2.2 billion, No. 378. Last year: $2.4 billion.
------

This article originally ran on CultureMap.

Trending News

Building Houston

 
 

Tvardi Therapeutics Inc. has fresh funds to support its drug's advancement in clinical trials. Photo via Getty Images

A Houston-based clinical-stage biopharmaceutical company has raised millions in its latest round.

Tvardi Therapeutics Inc. closed its $74 million series B funding round led by new investors New York-based Slate Path Capital, Florida-based Palkon Capital, Denver-based ArrowMark Partners, and New York-based 683 Capital, with continued support and participation by existing investors, including Houston-based Sporos Bioventures.

"We are thrilled to move out of stealth mode and partner with this lineup of long-term institutional investors," says Imran Alibhai, CEO at Tvardi. "With this financing we are positioned to advance the clinical development of our small molecule inhibitors of STAT3 into mid-stage trials as well as grow our team."

Through Slate Path Capital's investment, Jamie McNab, partner at the firm, will join Tvardi's board of directors.

"Tvardi is the leader in the field of STAT3 biology and has compelling proof of concept clinical data," McNab says in the release. "I look forward to partnering with the management team to advance Tvardi's mission to develop a new class of breakthrough medicines for cancer, chronic inflammation, and fibrosis."

Tvardi's latest fundraise will go toward supporting the company's products in their mid-stage trials for cancer and fibrosis. According to the release, Tvardi's lead product, TTI-101, is being studied in a Phase 1 trial of patients with advanced solid tumors who have failed all lines of therapy. So far, the drug has been well-received and shown multiple durable radiographic objective responses in the cancer patients treated.

Dr. Keith Flaherty, who is a member of Tvardi's scientific advisory board and professor of medicine at Harvard Medical School, offered his support of the company.

"STAT3 is a compelling and validated target. Beyond its clinical activity, Tvardi's lead molecule, TTI-101, has demonstrated direct downregulation of STAT3 in patients," he says in the release. "As a physician, I am eager to see the potential of Tvardi's molecules in diseases of high unmet medical need where STAT3 is a key driver."

Trending News